Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zettl

Showing results (861-870 of 888) with videos related to

Pageof 89
Sort By:
Neurology|October 1, 2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European CohortMarius Ringelstein, Susanna Asseyer, Gero Lindenblatt, et al.
Leukemia|February 7, 2012
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working GroupT M Westers, R Ireland, W Kern, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Journal of Medical Genetics|September 14, 2012
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjectsChristina M Lill, Tian Liu, Brit-Maren M Schjeide, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2020
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severityPatrick Ostkamp, Anke Salmen, Béatrice Pignolet, et al.
Journal of Neuroinflammation|January 21, 2012
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius, Klemens Ruprecht, Brigitte Wildemann, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Genetic Epidemiology|October 27, 2015
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome ArrayTheresa Dankowski, Dorothea Buck, Till F M Andlauer, et al.
Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.
Pageof 89

Showing results (861-870 of 888) with videos related to

Sort By:
Pageof 89
Neurology|October 1, 2024
Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European CohortMarius Ringelstein, Susanna Asseyer, Gero Lindenblatt, et al.
Leukemia|February 7, 2012
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working GroupT M Westers, R Ireland, W Kern, et al.
Therapeutic Advances in Neurological Disorders|August 23, 2021
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Der Nervenarzt|July 23, 2021
[Multiple sclerosis treatment consensus group (MSTCG): position paper on disease-modifying treatment of multiple sclerosis 2021 (white paper)]Heinz Wiendl, Ralf Gold, Thomas Berger, et al.
Journal of Medical Genetics|September 14, 2012
Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjectsChristina M Lill, Tian Liu, Brit-Maren M Schjeide, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2020
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severityPatrick Ostkamp, Anke Salmen, Béatrice Pignolet, et al.
Journal of Neuroinflammation|January 21, 2012
Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patientsSven Jarius, Klemens Ruprecht, Brigitte Wildemann, et al.
Arthritis Research & Therapy|May 17, 2011
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)Hans-Peter Tony, Gerd Burmester, Hendrik Schulze-Koops, et al.
Genetic Epidemiology|October 27, 2015
Successful Replication of GWAS Hits for Multiple Sclerosis in 10,000 Germans Using the Exome ArrayTheresa Dankowski, Dorothea Buck, Till F M Andlauer, et al.
Frontiers in Immunology|April 28, 2025
Worse recovery from acute attacks and faster disability accumulation highlights the unmet need for improved treatment in patients with late-onset neuromyelitis optica spectrum disorders (COPTER-LO study)Julian Reza Kretschmer, Daria Tkachenko, Tania Kümpfel, et al.
Pageof 89